Healthcare >> CEO Interviews >> May 29, 2000

Anna Gluskin – Generex Biotechnology Corporation (gnbt)

ANNA E. GLUSKIN is the President and Chief Executive Officer of Generex Biotechnology Corporation. Ms. Gluskin has held this senior position in the company since its inception. Within this capacity, Ms. Gluskin plans, co-ordinates and manages the business development activities of the company, leading up to the timely development of new and improved product processes. She provides leadership throughout the company and directs most of her efforts towards seeking new opportunities wherein Generex's platform technologies may effectively be utilized. Ms. Gluskin has spent much of her 25-year career within the global market in the areas of finance. She has successfully negotiated agreements for various ventures and developments worldwide. Since 1990, Ms. Gluskin has worked on a number of medically related projects where she has developed her skills in managing and directing several healthcare development groups. Profile
TWST: Please give us an overview of Generex Biotechnology.

Ms. Gluskin: Generex Biotechnology was founded in November 1995 by my

partners, Mark Perri and Rose Perri, and myself as a private